Efficacy and safety of luveltamab tazevibulin vs investigator’s choice of chemotherapy in patients with recurrent platinum-resistant ovarian cancer (PROC) expressing folate receptor alpha (FRα): The REFRaME-01 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase 2/3 study.

Ana  Oaknin

Consulting or Advisory Role - AGENUS; AstraZeneca; Clovis Oncology; Corcept Therapeutics; Daiichi Sankyo; Debiopharm Group; Deciphera; Eisai; Exelixis; Genmab; GlaxoSmithKline; Immunogen; ITeos Therapeutics; Merck Sharp & Dohme; Mersana; Myriad Genetics; Novocure; OneXerna Therapeutics, Inc.; PharmaMar; Regeneron; Roche; Seagen; Shattuck Labs; Sutro Biopharma; Zentalis

Research Funding - Abbvie (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Bristol-Myers Squibb International Corporation (BMS) (Inst); Clovis Oncology (Inst); Eisai (Inst); Immunogen (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); PharmaMar (Inst); Regeneron (Inst); Roche (Inst); Tesaro (Inst)

Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; PharmaMar; Roche

Jung-Yun  Lee

Consulting or Advisory Role - AstraZeneca; MSD; Roche; Takeda

Research Funding - Ascendis Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Eisai (Inst); Immunogen (Inst); Janssen Oncology (Inst); Merck (Inst); Mersana (Inst); MSD (Inst); Novartis (Inst); OncoQuest Pharmaceuticals (Inst); Roche (Inst); Seagen (Inst); Synthon (Inst); Takeda (Inst)

David  Cibula

No Relationships to Disclose

Yeh Chen  Lee

Speakers' Bureau - AstraZeneca

Research Funding - BeiGene (Inst)

Russell J.  Schilder

Consulting or Advisory Role - Celsion; Eisai; Incyte

Annika  Auranen

Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; MSD Oncology

Travel, Accommodations, Expenses - GlaxoSmithKline

Bo  Gao

Consulting or Advisory Role - BeiGene; IMPAC Medical Systems; IMPAC Medical Systems; MSD

David Shao Peng  Tan

Stock and Other Ownership Interests  - Asian Microbiome Library

Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; Merck Serono; MSD; Roche; Takeda

Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Eisai; Genmab; MSD; Roche

Research Funding - AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); BerGenBio (Inst); Byondis BV (Inst); Karyopharm Therapeutics (Inst); Roche (Inst); Zeria Pharmaceuticals Co Ltd (Inst)

(OPTIONAL) Uncompensated Relationships - Asia-Pacific Gynecologic Oncology Trials Group; Gynecologic Cancer Group Singapore; Gynecological Cancer InterGroup

Amit M.  Oza

Consulting or Advisory Role - AstraZeneca; MorphoSys

Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Merck (Inst)

(OPTIONAL) Uncompensated Relationships - Ozmosis Research

Rowan  Miller

Consulting or Advisory Role - AZD; Clovis Oncology; Ellipses Pharma; GlaxoSmithKline; Merck KGaA; Roche

Speakers' Bureau - AZD; Clovis Oncology; GlaxoSmithKline; Roche

Travel, Accommodations, Expenses - AstraZeneca; Tesaro

Vanda  Salutari

Honoraria - AstraZeneca; GlaxoSmithKline; MSD Oncology; Novocure; PharmaMar

Consulting or Advisory Role - AstraZeneca; Novocure

Travel, Accommodations, Expenses - GlaxoSmithKline; PharmaMar

Giulia  Tasca

Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; MSD Oncology

Speakers' Bureau - GlaxoSmithKline

Research Funding - GlaxoSmithKline

Travel, Accommodations, Expenses - Pharmamar

David M.  O'Malley

Consulting or Advisory Role - Adaptimmune; Agenus; AstraZeneca; Clovis Oncology; Corcept Therapeutics; DualityBio; Eisai; Elevar Therapeutics; GlaxoSmithKline; GOG Foundation; Immunogen; Imvax; Laekna Therapeutics; Merck; Mersana; Novartis; Novocure; Novocure; OncoC4; Onconova Therapeutics; Regeneron; Roche; Seagen; Sutro Biopharma; Umoja Biopharma; Verastem

Research Funding - Abbvie (Inst); Abbvie/Stemcentrx (Inst); Acerta Pharma (Inst); Advaxis (Inst); Ajinomoto (Inst); Ajinomoto (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BBI Healthcare (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clovis Oncology (Inst); Deciphera (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Ergomed (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Immunogen (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); NovoCure (Inst); OncoQuest (Inst); Pfizer (Inst); PharmaMar (Inst); Precision Therapeutics (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); SeaGen (Inst); Seagen (Inst); Sumitomo Dainippon Pharma Oncology, Inc. (Inst); Sutro Biopharma (Inst); Tesaro (Inst); TRACON Pharma (Inst); Verastem (Inst)

Bradley J.  Monk

Leadership - US Oncology

Honoraria - Acrivon Therapeutics; Adaptimmune; Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; HenRui; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Laekna Health Care; Merck; Mersana; Myriad Pharmaceuticals; Novartis; Novocure; OncoC4; Panavance Therapeutics; Pfizer; Pieris Pharmaceuticals; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics; Verastem; Zentalis

Consulting or Advisory Role - Adaptimmune; Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; Gradalis; HenRui; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Laekna Health Care; Merck; Mersana; Myriad Pharmaceuticals; Novartis; Novocure; OncoC4; Panavance Therapeutics; Pfizer; Pieris Pharmaceuticals; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics; Verastem; Zentalis

Speakers' Bureau - AstraZeneca; Clovis Oncology; Eisai; Merck; Roche/Genentech; TESARO/GSK

Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst)

Bhavana  Pothuri

Honoraria - Bio Ascend; OncLive; PER; Projects in Knowledge; YALE UNIVERSITY

Consulting or Advisory Role - AstraZeneca; Celsion; Curio Science; Eisai; GlaxoSmithKline; GOG Foundation; Immunogen; Imvax; Incyte; Incyte; InxMed; Lilly; Merck; Mersana; Onconova Therapeutics; Peerview; R-Pharm; Regeneron; Seagen; Signatera; Sutro Biopharma; WebMD

Research Funding - Acrivon Therapeutics (Inst); Agenus (Inst); AstraZeneca (Inst); Celgene (Inst); Celsion (Inst); Clovis Oncology (Inst); Eisai (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); InxMed (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Mersana (Inst); Novocure (Inst); NRG Oncology (Inst); Onconova Therapeutics (Inst); Seagen (Inst); Sutro Biopharma (Inst); Takeda (Inst); Tesaro (Inst); Toray Industries (Inst); VBL Therapeutics (Inst); Xencor (Inst)

Travel, Accommodations, Expenses - GOG Foundation; Merck; Seagen

Other Relationship - Society of Gynecologic Oncology

Lin  Lu

Employment - Sutro Biopharma

Stock and Other Ownership Interests  - Sutro Biopharma

Craig  Berman

Employment - Sutro Biopharma

Stock and Other Ownership Interests  - Sutro Biopharma

Anne  Borgman

Employment - Sutro Biopharma

Stock and Other Ownership Interests  - Sutro Biopharma

R. Wendel  Naumann

Consulting or Advisory Role - Agenus; AstraZeneca; Bristol-Myers Suibb; Eisai; EMD Serono; Genelux; GlaxoSmithKline/Tesaro; GOG Partners; Immunogen; Laekna Therapeutics; Merck Sharp & Dohme; Seagen; Sutro Biopharma

Speakers' Bureau - Seagen

Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline/Tesaro (Inst); Gynecologic Oncology Group (Inst); Mersana (Inst); OncoMed (Inst); Sutro Biopharma (Inst)